Seattle Genetics to Host Conference Call & Webcast Discussion of Fourth Quarter & Full Year 2018 Financial Results on Februar...
January 22 2019 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it
will report its fourth quarter and full year 2018 financial results
on Thursday, February 7, 2019 after the close of financial markets.
Following the announcement, company management will host a
conference call and webcast discussion of the results and provide a
general corporate update. Access to the event can be obtained as
follows:
LIVE access on Thursday, February 7, 20191:30 p.m. Pacific Time
/ 4:30 p.m. Eastern Time
- Telephone 877-260-1479 (domestic) or +1
334-323-0522 (international); conference ID 1660553
- Webcast available at
www.seattlegenetics.com in the Investors section
REPLAY access
- Telephone replay will be available
beginning at approximately 4:30 p.m. PT on Thursday, February 7,
2019 through 5:00 p.m. PT on Monday, February 11, 2019 by calling
888-203-1112 (domestic) or +1 719-457-0820 (international);
conference ID 1660553
- Webcast replay will be available on the
Seattle Genetics website at www.seattlegenetics.com in the
Investors section
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes
transformative therapies targeting cancer to make a meaningful
difference in people’s lives. ADCETRIS® (brentuximab vedotin)
utilizes the company’s industry-leading antibody-drug conjugate
(ADC) technology and is currently approved for the treatment of
multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company
has established a pipeline of novel targeted therapies at various
stages of clinical testing, including three in ongoing pivotal
trials for solid tumors. Enfortumab vedotin for metastatic
urothelial cancer and tisotumab vedotin for metastatic cervical
cancer utilize our proprietary ADC technology. Tucatinib, a small
molecule tyrosine kinase inhibitor, is in a pivotal trial for
HER2-positive metastatic breast cancer. In addition, we are
leveraging our expertise in empowered antibodies to build a
portfolio of proprietary immuno-oncology agents in clinical trials
targeting hematologic malignancies and solid tumors. The company is
headquartered in Bothell, Washington, and has a European
office in Switzerland. For more information on our robust
pipeline, visit www.seattlegenetics.com and follow
@SeattleGenetics on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190122005091/en/
InvestorsPeggy Pinkston(425)
527-4160ppinkston@seagen.com
MediaMonique Greer(425) 527-4641mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024